Your browser doesn't support javascript.
loading
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
André, Fabrice; O'Regan, Ruth; Ozguroglu, Mustafa; Toi, Masakazu; Xu, Binghe; Jerusalem, Guy; Masuda, Norikazu; Wilks, Sharon; Arena, Francis; Isaacs, Claudine; Yap, Yoon-Sim; Papai, Zsuzsanna; Lang, Istvan; Armstrong, Anne; Lerzo, Guillermo; White, Michelle; Shen, Kunwei; Litton, Jennifer; Chen, David; Zhang, Yufen; Ali, Shyanne; Taran, Tetiana; Gianni, Luca.
Afiliación
  • André F; Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.
  • O'Regan R; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Ozguroglu M; Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul, Turkey.
  • Toi M; Kyoto University, Sakyo-ku, Kyoto, Japan.
  • Xu B; Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.
  • Jerusalem G; Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège, Belgium.
  • Masuda N; NHO Osaka National Hospital, Chuou-ku, Osaka, Japan.
  • Wilks S; Cancer Care Centers of South Texas, San Antonio, TX, USA.
  • Arena F; NYU Langone Arena Oncology, Lake Success, NY, USA.
  • Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  • Yap YS; National Cancer Centre Singapore, Singapore.
  • Papai Z; Oncology Department, Military Hospital, Budapest, Hungary.
  • Lang I; Orszagos Onkologiai Intezet, Budapest, Hungary.
  • Armstrong A; Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Lerzo G; Sanatorio de la Providencia, Buenos Aires, Argentina.
  • White M; Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC, Australia.
  • Shen K; Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China.
  • Litton J; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen D; Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Zhang Y; Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Ali S; Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Taran T; Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Gianni L; Ospedale San Raffaele Scientific Institute, Milan, Italy. Electronic address: gianni.luca@hsr.it.
Lancet Oncol ; 15(6): 580-91, 2014 May.
Article en En | MEDLINE | ID: mdl-24742739
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Sirolimus Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Sirolimus Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Francia